Pharma Focus America

Debiopharm and Genome & Company Enter Agreement for Potential First-in-Class Oncology Antibody Drug Conjugate Family

Tuesday, June 04, 2024

Debiopharm, a Swiss-based biopharmaceutical company, has recently announced an exclusive licensing agreement with Genome & Company, a biotechnology firm based in South Korea. This collaboration aims to develop antibody drug conjugates (ADCs) with groundbreaking potential in treating cancer. Debiopharm will combine Genome & Company's specific antibodies with its own Multilink™ linker technology to create innovative therapeutic agents targeting hard-to-treat cancers.

ADCs are advanced oncology treatments comprising a monoclonal antibody, a stable linker, and potent cytotoxic payloads. These compounds precisely target cancer cells, delivering toxic payloads while minimizing damage to healthy tissues. Linker design is crucial for effective drug release, and Debiopharm's Multilink™ technology offers superior stability, enhancing treatment specificity and effectiveness.

Frederic Levy, Debiopharm's Chief Scientific Officer, emphasized the synergy between Genome & Company's antibodies and their linker technology, highlighting the potential for developing groundbreaking ADCs. Debiopharm is dedicated to expanding its ADC platform, exploring bispecific ADCs and innovative technologies to accelerate patient access to these treatments.

Genome & Company's CEO, Yoo Seok Hong, expressed excitement about the collaboration's potential and their pipeline of novel anti-cancer drugs. Leveraging Genome & Company's research capabilities, this agreement marks a significant step in advancing anti-cancer therapies.

Multilink™ is a cleavable linker platform enabling the attachment of multiple payloads to antibodies, enhancing therapeutic effects. Debiopharm's ADC portfolio includes promising candidates such as Debio 1562M and Debio 0532, targeting acute myeloid leukemia and solid tumors, respectively. These ADCs, coupled with their innovative linker technology, represent a commitment to delivering impactful treatments to patients.

Genome & Company specializes in discovering and developing novel cancer antibodies, leveraging their unique GNOCLE™ platform. This partnership signifies a strategic alliance to advance cancer therapeutics and underscores both companies' dedication to improving patient outcomes.

 

Source: businesswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024